Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways

J Diabetes Complications. 2016 Jul;30(5):760-9. doi: 10.1016/j.jdiacomp.2016.03.013. Epub 2016 Mar 17.

Abstract

Aims: The aim of this research was to investigate the effects of cyclopropanyldehydrocostunolide (also named LJ), a derivative of sesquiterpene lactones (SLs), on high glucose (HG)-induced podocyte injury and the associated molecular mechanisms.

Methods: Differentiated mouse podocytes were incubated in different treatments. The migration and albumin filtration of podocytes were examined by Transwell filters. The protein and mRNA levels of MCP-1 were measured using enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR (q-PCR). Protein expression and phosphorylation were detected by western blot, and the nuclear translocation of NF-κB was performed with a confocal microscope. The gene expression of the receptor activator for NF-κB (RANK) was silenced by small interfering RNA (siRNA).

Results: Our results showed that HG enhanced migration, albumin filtration and MCP-1 expression in podocytes. At the molecular level, HG promoted the phosphorylation of NF-κB/p65, IKKβ, IκBα, mitogen-activated protein kinase (MAPK) and the nuclear translocation of p65. LJ reversed the effects of HG in a dose-dependent manner. Furthermore, our data provided the first demonstration that the receptor activator for NF-κB ligand (RANKL) and its cognate receptor RANK were overexpressed in HG-induced podocytes and were downregulated by LJ. RANK siRNA also attenuated HG-induced podocyte injury and markedly inhibited the activation of NF-κB and MAPK signaling pathways.

Conclusions: LJ attenuates HG-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways.

Keywords: LJ; Mitogen-activated protein kinase; NF-κB; Receptor activator for NF-κB; Receptor activator for NF-κB ligand.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Active Transport, Cell Nucleus / drug effects
  • Animals
  • Biomarkers / metabolism
  • Cell Line, Transformed
  • Cell Movement / drug effects
  • Chemokine CCL2 / agonists
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Diabetic Nephropathies / prevention & control
  • Gene Expression Regulation / drug effects
  • Hyperglycemia / complications
  • Hyperglycemia / drug therapy
  • Hyperglycemia / metabolism
  • Hyperglycemia / pathology
  • Hypoglycemic Agents / pharmacology*
  • Lactones / pharmacology*
  • MAP Kinase Signaling System / drug effects
  • Membrane Proteins / agonists
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Phosphorylation / drug effects
  • Podocytes / drug effects*
  • Podocytes / metabolism
  • Podocytes / pathology
  • Protein Processing, Post-Translational / drug effects
  • RANK Ligand / antagonists & inhibitors*
  • RANK Ligand / metabolism
  • RNA Interference
  • Receptor Activator of Nuclear Factor-kappa B / antagonists & inhibitors*
  • Receptor Activator of Nuclear Factor-kappa B / genetics
  • Receptor Activator of Nuclear Factor-kappa B / metabolism
  • Sesquiterpenes / pharmacology*
  • Transcription Factor RelA / antagonists & inhibitors*
  • Transcription Factor RelA / metabolism

Substances

  • Biomarkers
  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Hypoglycemic Agents
  • Lactones
  • Membrane Proteins
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Rela protein, mouse
  • Sesquiterpenes
  • Tnfrsf11a protein, mouse
  • Tnfsf11 protein, mouse
  • Transcription Factor RelA
  • nephrin